Kawashima K, Amano H, Fujimoto K, Suzuki T, Fujii T, Mochizuki S, Tomiyama A
Department of Pharmacology, Kyoritsu College of Pharmacy, Minato-ku, Tokyo, Japan.
J Cardiovasc Pharmacol. 1996 Mar;27(3):411-6. doi: 10.1097/00005344-199603000-00014.
KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and locomotor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Although KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.
非肽类血管紧张素 II 1 型受体拮抗剂 KT3-671 连续 3 周每日给予 20 周龄的易中风自发性高血压大鼠(SHRSP)。通过无线电遥测技术研究其对收缩压、平均动脉压和舒张压(SAP、MAP、DAP)、心率和运动活动的影响。观察到血压、心率和运动活动存在明显的昼夜变化,与光周期同步。每日口服(p.o)剂量为 10 mg/kg 的 KT3-671 可显著且持续降低血压,预防高血压的发展。KT3-671 降低 SAP 的幅度大于 DAP,表明它可能同时影响血管张力和心输出量。虽然 KT3-671 不影响心率和运动活动的昼夜节律,但确实导致心率略有但显著降低。在给予 KT3-671 后 23 小时测定的 MAP 显示,从治疗第 2 天到停药后第 3 天有显著降低,表明降压作用持续时间长。停药后血压没有反跳性升高。这些结果表明,KT3-671 可能对高血压治疗有潜在用途。